Jump to main content
Jump to site search


Biocompatible and Blood-Brain Barrier Permeable Carbon Dots for Inhibition of Aβ Fibrillation and Toxicity, and BACE1 Activity

Abstract

Amyloid-β peptides (Aβ) fibrillation is pathologically associated with Alzheimer’s disease (AD), resulting in the development of Aβ inhibitor essential for the treatment of AD. However, the design of potent agents which can target upstream secretases, inhibit Aβ toxicity and aggregation, as well as cross the blood-brain barrier (BBB) remains challenging. Herein, we investigated carbon dots for AD treatment in vitro via experimental and computational methods for the first time. These results demonstrate a novel strategy for the discovery of novel antiamyloidogenic agents for AD treatments.

Back to tab navigation

Supplementary files

Publication details

The article was received on 16 Jun 2017, accepted on 07 Jul 2017 and first published on 12 Jul 2017


Article type: Communication
DOI: 10.1039/C7NR04352J
Citation: Nanoscale, 2017, Accepted Manuscript
  •   Request permissions

    Biocompatible and Blood-Brain Barrier Permeable Carbon Dots for Inhibition of Aβ Fibrillation and Toxicity, and BACE1 Activity

    X. Han, Z. Jing, W. Wu, B. Zou, Z. Peng, P. Ren, A. Wikramanayake, Z. Lu and R. Leblanc, Nanoscale, 2017, Accepted Manuscript , DOI: 10.1039/C7NR04352J

Search articles by author

Spotlight

Advertisements